South Korea · Delayed Price · Currency is KRW Keeps Biopharma Statistics
Total Valuation
Keeps Biopharma has a market cap or net worth of KRW 113.24 billion. The enterprise value is 196.60 billion.
| Market Cap | 113.24B |
| Enterprise Value | 196.60B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Keeps Biopharma has 20.08 million shares outstanding. The number of shares has increased by 4.40% in one year.
| Current Share Class | 20.08M |
| Shares Outstanding | 20.08M |
| Shares Change (YoY) | +4.40% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 4.13% |
| Owned by Institutions (%) | 4.25% |
| Float | 14.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.51 |
| PB Ratio | 1.42 |
| P/TBV Ratio | 10.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.89 |
| EV / EBITDA | 68.70 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 1.20.
| Current Ratio | 1.06 |
| Quick Ratio | 0.61 |
| Debt / Equity | 1.20 |
| Debt / EBITDA | 19.69 |
| Debt / FCF | -2.18 |
| Interest Coverage | -0.08 |
Financial Efficiency
Return on equity (ROE) is -15.58% and return on invested capital (ROIC) is -0.41%.
| Return on Equity (ROE) | -15.58% |
| Return on Assets (ROA) | -0.17% |
| Return on Invested Capital (ROIC) | -0.41% |
| Return on Capital Employed (ROCE) | -0.45% |
| Weighted Average Cost of Capital (WACC) | 8.09% |
| Revenue Per Employee | 2.02B |
| Profits Per Employee | -113.66M |
| Employee Count | 109 |
| Asset Turnover | 0.99 |
| Inventory Turnover | 7.04 |
Taxes
| Income Tax | -602.89M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.63% in the last 52 weeks. The beta is 1.03, so Keeps Biopharma's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -51.63% |
| 50-Day Moving Average | 5,792.20 |
| 200-Day Moving Average | 7,810.35 |
| Relative Strength Index (RSI) | 47.65 |
| Average Volume (20 Days) | 26,488 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Keeps Biopharma had revenue of KRW 220.48 billion and -12.39 billion in losses. Loss per share was -619.91.
| Revenue | 220.48B |
| Gross Profit | 39.55B |
| Operating Income | -598.90M |
| Pretax Income | -13.72B |
| Net Income | -12.39B |
| EBITDA | 4.84B |
| EBIT | -598.90M |
| Loss Per Share | -619.91 |
Balance Sheet
The company has 28.99 billion in cash and 95.26 billion in debt, with a net cash position of -66.27 billion or -3,300.79 per share.
| Cash & Cash Equivalents | 28.99B |
| Total Debt | 95.26B |
| Net Cash | -66.27B |
| Net Cash Per Share | -3,300.79 |
| Equity (Book Value) | 79.65B |
| Book Value Per Share | 3,119.31 |
| Working Capital | 6.47B |
Cash Flow
In the last 12 months, operating cash flow was -11.58 billion and capital expenditures -32.19 billion, giving a free cash flow of -43.77 billion.
| Operating Cash Flow | -11.58B |
| Capital Expenditures | -32.19B |
| Depreciation & Amortization | 5.44B |
| Net Borrowing | 18.73B |
| Free Cash Flow | -43.77B |
| FCF Per Share | -2,179.89 |
Margins
Gross margin is 17.94%, with operating and profit margins of -0.27% and -5.62%.
| Gross Margin | 17.94% |
| Operating Margin | -0.27% |
| Pretax Margin | -6.22% |
| Profit Margin | -5.62% |
| EBITDA Margin | 2.19% |
| EBIT Margin | -0.27% |
| FCF Margin | n/a |
Dividends & Yields
Keeps Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.40% |
| Shareholder Yield | -4.40% |
| Earnings Yield | -10.94% |
| FCF Yield | -38.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 20, 2020. It was a forward split with a ratio of 3.
| Last Split Date | May 20, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Keeps Biopharma has an Altman Z-Score of 1.7 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.7 |
| Piotroski F-Score | 4 |